Last reviewed · How we verify
A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
This is a single-center, open-label study to evaluate the safety and efficacy of A-CAR028 in relapsed/refractory acute myeloid leukemia patients
Details
| Lead sponsor | First Affiliated Hospital of Zhejiang University |
|---|---|
| Phase | PHASE1 |
| Status | RECRUITING |
| Enrolment | 20 |
| Start date | Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Dec 31 2027 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Acute Myeloid Leukemia (AML)
- CAR-T Cell Therapy
Interventions
- A-CAR028
Countries
China